Back to Search Start Over

Patient and healthcare provider perceptions of acceptability of fingerstick point-of-care hepatitis C testing at Aboriginal Community Controlled Health Services in Australia.

Authors :
Lafferty L
Beadman M
Ward J
Flynn E
Hosseini-Hooshyar S
Martinello M
Treloar C
Source :
The International journal on drug policy [Int J Drug Policy] 2024 Mar; Vol. 125, pp. 104335. Date of Electronic Publication: 2024 Feb 10.
Publication Year :
2024

Abstract

Background: Hepatitis C (HCV) is highly prevalent in First Nations communities globally. Barriers in the uptake of testing and treatment create challenges to realise elimination of HCV in these communities. In efforts to reduce barriers to testing and treatment, the SCALE-C study implemented an HCV test-and-treat intervention integrating point-of-care HCV testing and FibroScan®. SCALE-C was carried out at four Aboriginal Community Controlled Health Services (ACCHS; renowned for providing culturally safe care) in four regional towns in Australia. This qualitative analysis sought to understand healthcare provider and patient perceptions of acceptability of a community-based HCV test-and-treat intervention within ACCHS.<br />Methods: Semi-structured interviews were undertaken with 23 patient participants and 14 healthcare personnel (including Aboriginal Health Workers/Practitioners, nurses, general practitioners, and practice managers) from across the four ACCHS involved in SCALE-C. A coding framework was developed among study authors and informed by Sekhon's Theoretical Framework of Acceptability.<br />Results: The SCALE-C intervention enabled opportunities for healthcare providers to listen to patients, and for patients to feel heard (affective attitude). HCV testing was opportunistic and often occurred outside of the allocated SCALE-C clinical hours (burden). For patients, HCV testing within SCALE-C was viewed as a moral responsibility and ensured protection of self and others (ethicality). For personnel, SCALE-C (including following up visits) was regarded as an opportunity to engage with patients especially those with complex health needs which may be unrelated to HCV risk factors (ethicality). Patients and personnel widely regarded the SCALE-C intervention to be effective, and the test-and-treat model was preferable for both patients and personnel.<br />Conclusion: The SCALE-C intervention was broadly perceived to be acceptable among both healthcare providers and patients within ACCHS. Whilst the prioritisation of HCV was viewed as increasing patient engagement, it was also regarded as an opportunity for addressing other healthcare needs within Aboriginal communities. HCV test-and-treat models of care delivered by ACCHS simplify the HCV care pathway and ensure all HCV care is provided in a culturally safe setting (e.g., patients did not need to attend external services such as pathology).<br />Competing Interests: Declaration of competing interest LL has received speaker fees from AbbVie and Gilead Sciences. MB, JW, EF, and SH-H have nothing to declare. MM reports salary support from the Australian National Health and Medical Research Council Early Career Fellowship. CT has received speaker fees from AbbVie and Gilead Sciences.<br /> (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1873-4758
Volume :
125
Database :
MEDLINE
Journal :
The International journal on drug policy
Publication Type :
Academic Journal
Accession number :
38342050
Full Text :
https://doi.org/10.1016/j.drugpo.2024.104335